Patent ID: 11884723
Assignee: OSE IMMUNOTHERAPEUTICS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 6:
7. The method of claim 1, wherein at least one antigen:
(i) selected from the group consisting of antigens from Human Papilloma Virus, Epstein-Barr Virus, Merkel cell polyomavirus, Human Immunodeficiency Virus, Human T-cell Leukemia Virus, Human Herpes Virus 8, Hepatitis B virus, Hepatitis C virus, HCV, HBC, and Cytomegalovirus, or
(ii) selected from the group of single-point mutated antigens derived from the group consisting of the antigens of ctnnb1 gene, casp8 gene, her2 gene, p53 gene, kras gene, and nras gene, or
(iii) selected from the group of tumor antigens issued or derived from the group consisting of ras oncogene, BCR-ABL tumor antigens, ETV6-AML1 tumor antigens, melanoma-antigen encoding genes (MAGE), BAGE antigens, GAGE antigens, ssx antigens, ny-eso-1 antigens, cyclin-A1 tumor antigens, MART-1 antigen, gp100 antigen, CD19 antigen, prostate specific antigen, prostatic acidic phosphatase antigen, carcinoembryonic antigen, alphafetoprotein antigen, carcinoma antigen 125, mucin 16 antigen, mucin 1 antigen, human telomerase reverse transcriptase antigen, EGFR antigen, MOK antigen, RAGE-1 antigen, PRAME antigen, wild-type p53 antigen, oncogene ERBB2 antigen, sialyl-Tn tumor antigen, Wilms tumor 1 antigen, mesothelin antigen, carbohydrate antigens, B-catenin antigen, MUM-1 antigen, CDK4 antigen, ERBB2IP antigen, and Melan-A melanoma tumor-associated antigen (TAA),
is expressed or has been detected in the subject.